Endologix (NSDQ:ELGX) said yesterday that its board of directors set the ratio for its reverse stock split at 1-for-10. Beginning today, Endologix’s common stock will trade on the Nasdaq Global Select market on a reverse stock split-adjusted basis, the Irvine, Calif.-based company reported. Following the reverse split, there will be roughly 10.3 million shares of issued […]
Endologix misses the mark with Q4, 2018 numbers
Endologix (NSDQ:ELGX) this week posted fourth-quarter and full-year results that missed the consensus forecasts for sales and earnings for both periods. The Irvine, Calif.-based stent graft maker’s losses grew 78.7% to -$26.0 million, or -26¢ per share, on sales growth of -18.6% to $24.0 million for the three months ended Dec. 31, 2018, compared with the […]
Endologix shareholders approve reverse split
Endologix (NSDQ:ELGX) shareholders last week approved an upcoming reverse split of the company’s shares, according to a recently posted SEC filing. Shareholders in the Irvine, Calif.-based company voted to approve a reverse stock split “at a ratio not less than 1-for-5 and not greater than 1 for-10,” according to the SEC filing. The exact ratio has not yet been […]
CE Mark suspended for Endologix Nellix stent graft
Endologix (NSDQ:ELGX) said yesterday that the CE Mark approval for its Nellix stent graft system designed for treating abdominal aortic aneurysms was suspended by its notified body, GMED. The move follows a halt to unrestricted sales of the stent grafts and a voluntary recall of all existing inventory that the Irvine, Calif.-based company announced earlier this month. […]
JenaValve names Kilcoyne as CEO | Personnel Moves – January 15, 2019
JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he […]
Si-Bone tops estimates with Q4 prelims | Wall Street Beat
Si-Bone (NSDQ:SIBN) said today that it expects to record fourth-quarter sales of $15.4 million to $15.6 million, up 12 – 13% from the same period last year. The company pegged its full-year sales for 2018 between $55.2 million and $55.4 million, up 15% from 2017. Analysts on Wall Street are expecting Si-Bone to post Q4 sales […]
Endologix recalls Nellix stent graft, bans off-label use
Endologix (NSDQ:ELGX) said today that it’s halting the unrestricted sale of its Nellix stent graft for treating abdominal aortic aneurysms and limiting its use to pre-screened patients under a clinical protocol. “We monitor the performance of the Nellix system through clinical trials, our complaint monitoring system, physician interaction and available publications,” CMO Dr. Matt Thompson said […]
Endologix posts Street-beating Q3
Endologix (NSDQ:ELGX) today posted third quarter earnings that beat expectation on Wall Street and reiterated earlier guidance for the remaining year. The Irvine, Calif.-based company posted losses of $10.1 million, or 12¢ per share, on sales of $34.8 million for the three months ended September 30, seeing losses shrink 29.1% while sales shrunk 24.4% compared with […]
Endologix launches $20m offering
Endologix (NSDQ:ELGX), looking to refinance its debt, said it’s floating $20 million worth of its own shares in a public offering. The Irvine, Calif.-based stent graft maker said the offering also includes a 30-day underwriter’s option worth another $3 million. Endologix said it plans to use the proceeds to pay off $18.3 million worth of 2.25% […]
FDA: Endologix recall of AFX stent graft is Class I
Endologix (NSDQ:ELGX) said late last week that the FDA classified its voluntary recall of AFX Endovascular abdominal aortic aneurysm stent graft systems as Class I. Class I recall designations, the FDA’s most serious classification of recall, are used when there is a reasonable probability that product use could cause serious adverse health consequences or death. The […]
Endologix soars on Q3 prelims beat, raised outlook
Endologix (NSDQ:ELGX) share prices opened up nearly 28% today after the stent graft maker’s preliminary third-quarter sales beat the consensus forecast and it raised the bottom of its top-line outlook for the rest of the year. Irvine, Calif-based Endologix said it expects to report sales of $34.3 million to $34.7 million for the three months ended […]
- 1
- 2
- 3
- …
- 9
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube